Treatment with Antiangiogenic Drugs in Multiple Lines in Patients with Metastatic Colorectal Cancer: Meta-Analysis of Randomized Trials

por Hofheinz, R.-D., Ronellenfitsch, U., Kubicka, S., Falcone, A., Burkholder, I., Hacker, U. T.
Publicado 2016

Capecitabine-associated hand–foot–skin reaction is an independent clinical predictor of improved survival in patients with colorectal cancer

por Hofheinz, R-D, Heinemann, V, von Weikersthal, L F, Laubender, R P, Gencer, D, Burkholder, I, Hochhaus, A, Stintzing, S
Publicado 2012

Height of Rectal Cancer: A Comparison between Rectoscopic and Different MRI Measurements

por Attenberger, U. I., Winter, J., Harder, F. N., Burkholder, I., Dinter, D., Kaltschmidt, S., Kienle, P., Schoenberg, S. O., Hofheinz, R.
Publicado 2020

A clinical phase II study with sorafenib in patients with progressive hormone-refractory prostate cancer: a study of the CESAR Central European Society for Anticancer Drug Research...

por Steinbild, S, Mross, K, Frost, A, Morant, R, Gillessen, S, Dittrich, C, Strumberg, D, Hochhaus, A, Hanauske, A-R, Edler, L, Burkholder, I, Scheulen, M
Publicado 2007